Generic Name and Formulations:
Succimer 100mg; caps.
Recordati Rare Diseases, Inc.
Indications for CHEMET:
Lead poisoning in children with blood lead levels >45micrograms/dL.
May swallow caps whole or put contents onto a small amount of soft food or a spoon and swallow, followed by fruit drink. <12months: not recommended. ≥12months: initially 10mg/kg (or 350mg/m2) every 8 hours for 5 days, then reduce frequency to every 12 hours for 14 more days. Allow at least 14 days between courses unless blood lead levels indicate need for more prompt treatment. Treatment for more than 3 consecutive weeks: not recommended.
Monitor for rebound elevated lead levels by measuring blood levels at least once weekly. Maintain adequate hydration. Monitor renal and hepatic function. Monitor for neutropenia; instruct patients to report any sign of infection or rash. Renal impairment. History of hepatic dysfunction. Find and remove source of lead from environment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Other concomitant chelation therapy (e.g., EDTA): not recommended. False (+) results with nitroprusside test (e.g., Ketostix).
GI upset, elevated serum transaminases, rash, pain, cramps, flu-like symptoms, dizziness, drowsiness, paresthesia; neutropenia, mucocutaneous vesicular eruptions (rare).
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D